On the recordDecember 12, 2019
We have no further speakers on this side, and I am prepared to close. Mr. Chair, I respect the opinions of Mr. Walden. We have worked in a bipartisan fashion on several issues before in Energy and Commerce, but I believe the claim that this would increase costs is simply false. Like the Senate Finance Committee that is moving forward with this proposition on biosimilars, we believe it is a way to lower costs. To date, the nine biosimilars accessible to patients are at an average discount of 28 percent. It is simply a false claim that a biosimilar would not launch at a lower price. Certainly, we must do better. We are reminded constantly that we can do better and we must do better. As the namesake of this legislation had constantly implored, Representative Elijah Cummings always knew that we must score for the public. That is why we must pass this amendment. Mr. Chair, I yield back the balance of my time.
